References
- GirouardNSoucyNPatient considerations in the management of multiple sclerosis: development and clinical utility of oral agentsPatient Prefer Adherence2011510110821448467
- National Multiple Sclerosis SocietyFact sheet: multiple sclerosis [webpage on the Internet]New York, NYNational Multiple Sclerosis Society2012 Available from: http://www.nationalmssociety.org/chapters/mnm/mediacenter/factsheetmultiplesclerosis/index.aspxAccessed October 18, 2012
- GiovannoniGSouthamEWaubantESystematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherenceMult Scler201218793294622249762
- KapposLRadueEWO’ConnorPfor FREEDOMS Study GroupA placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisN Engl J Med2010362538740120089952
- CohenJABarkhofFComiGfor TRANSFORMS Study GroupOral fingolimod or intramuscular interferon for relapsing multiple sclerosisN Engl J Med2010362540241520089954
- RoskellNSZimovetzEARycroftCEEckertBJTyasDAAnnualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimodCurr Med Res Opin201228576778022462530
- AgashivalaNWuNAbouzaidSComparison of compliance with fingolimod and other first-line disease-modifying treatments among patients with multiple sclerosisProceedings of the Academy of Managed Care Pharmacy (AMCP) Education ConferenceOctober 3–5, 2012Cincinnati, OH, USA
- AgashivalaNWuNWuYKimEBoulangerLBrandesDComparison of time to discontinuation among multiple sclerosis patients receiving fingolimod and other first-line disease-modifying treatmentsProceedings of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) CongressOctober 10–13, 2012Lyon, France
- O’RourkeKEHutchinsonMStopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patternsMult Scler2005111465015732266
- TremlettHLOgerJInterrupted therapy: stopping and switching of the beta-interferons prescribed for MSNeurology20036155155412939437
- Gilenya®(fingolimod) [package insert]East Hanover, NJNovartis Pharmaceuticals Corporation2010
- DiMarcoJPO’ConnorPCohenJAFingolimod treatment initiation experience: cardiac and Holter electrocardiogram findings from three phase 3 studiesProceedings of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) CongressOctober 10–13, 2012Lyon, France
- KurtzkeJFRating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)Neurology19833311144414526685237
- MotlRWFernhallBMcAuleyECutterGPhysical activity and self-reported cardiovascular comorbidities in persons with multiple sclerosis: evidence from a cross-sectional analysisNeuroepidemiology201136318319121597305
- HoholMJOravEJWeinerHLDisease steps in multiple sclerosis: a simple approach to evaluate disease progressionNeurology19954522512557854521
- KobeltGBergJAtherleyDHadjimichaelOCost and quality of life in multiple sclerosis: a cross-sectional study in the United StatesNeurology200666111696170216769943
- SchwartzCEVollmerTLeeHReliability and validity of two self-report measures of impairment and disability for MS. North American Research Consortium on Multiple Sclerosis Outcomes Study GroupNeurology199952163709921850
- AtkinsonMJSinhaAHassSLValidation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic diseaseHealth Qual Life Outcomes200421214987333